Funding: Health Foundation, ESVS Economic evaluation alongside clinical trials: The GALA trial Manuel Gomes, Marta Soares, Jo Dumville, David Torgerson.

Slides:

Advertisements

Similar presentations

ECONOMIC EVALUATION WHY DO YOU NEED TO BOTHER? JUDITH BOSMANS.

Advertisements

USE OF EVIDENCE IN DECISION MODELS: An appraisal of health technology assessments in the UK Nicola Cooper Centre for Biostatistics & Genetic Epidemiology,

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

Chronic Obstructive Pulmonary Disease Research Opportunity Chronic Obstructive Pulmonary Disease (COPD) Dr Ian Williams Greater Metro South Brisbane Medicare.

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

COURAGE Economic Results of the COURAGE Trial William S. Weintraub, MD Chief of Cardiology Christiana Care Health System Professor of Medicine, Thomas.

Introduction to Pharmacoeconomics

Making Decisions in Health Care: Cost-effectiveness and the Value of Evidence Karl Claxton Centre for Health Economics, Department of Economics and Related.

HERU is supported by the Chief Scientist Office of the Scottish Government Health Directorates and the University of Aberdeen. The author accepts full.

Transforming the cost-effectiveness threshold into a ‘value threshold’ Initial findings from a simulation model Mike Paulden and Christopher McCabe.

Cost-benefit analysis of nitrous oxide in major surgery Presenter: Dr Alison Graham 2 nd year Anaesthesia Advanced Trainee Co-Authors: Prof Paul S. Myles,

Pharmacoeconomics David Matthews 2012 AMCP P&T Competition National Finalist The Ohio State University AMCP Chapter October 9 th, 2012 An Introduction.

A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)

Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.

The Cost-Effectiveness and Value of Information Associated with Biologic Drugs for the Treatment of Psoriatic Arthritis Y Bravo Vergel, N Hawkins, C Asseburg,

The Role of Trial-based Economic Evaluation in Health Care Decision Making Discussion Mark Sculpher Centre for Health Economics University of York iHEA,

Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.

Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.

Do we need economics in medicine?. Edmund Burke, 1790 dcist.com/2007/12/10/revisiting_edmu.php “…the age of chivalry is gone. That of sophisters, economists,

Current Approaches in European Health Care Policy What models can balance the needs of payors and industry?

Learning Objectives Describe the use of the Outcomes Impact Analysis model to assess economic impact of a CME activity Discuss the potential role of Outcomes.

Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 1: Introduction Sept 3, 2008.

These slides were released by the speaker for internal use by Novartis.

Funding: Health Foundation, ESVS The implications of the GALA trial: General Anaesthesia vs Local (regional) Anaesthesia for Carotid Surgery 3 rd UK Stroke.

PHAR 310: Pharmacoeconomics

EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.

1 OECD Handbook on Measuring Volume Output of Education and Health Chapter 3: Health Sandra Hopkins OECD Health Division June 2007.

Types of analysis. Simulation rationale u Each patient’s natural history is random, but guided by underlying parameters. u With sufficiently large number.

Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 4: Measuring costs - Part 1 Sept 15,

HTA – Cost Containment or Quality Instrument? Bengt Jönsson Stockholm School of Economic.

Economic evaluation of drugs for rare diseases CENTRE FOR HEALTH ECONOMICS K Claxton, C McCabe, A Tsuchiya Centre for Health Economics and Department of.

Phaedra Corso, Ph.D. Associate Professor College of Public Health University of Georgia Program Evaluation from an Economic Perspective.

Cost-Effectiveness of Palliative Team Care For Patients Nearing End-Of-Life Society for Medical Decision Making 36 st Annual Meeting – Miami, Florida October.

VASCULAR ANAESTHESIA TIPS AND TRICKS OR HOW NOT TO GET CAUGHT! DR KEVIN M SADLER STH.

Basic Economic Analysis David Epstein, Centre for Health Economics, York.

Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.

انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.

Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.

Funding: Health Foundation, ESVS Surgical Variations GA LA n = 1720 n = 1730 Trainee surgeon: n (%) 242 (14%) 210 (12%) Trainee Anaesthetist: n (%) 246.

PHARMAC What is PHARMAC? PHARMAC - the Pharmaceutical Management AgencyPHARMAC - the Pharmaceutical Management Agency A New Zealand Government Agency (Crown.

The Use of Pharmacoeconomics and Pharmacoepidemiology in Your Local MTF P&T Process by Marv Shepherd, Ph.D. Jim Wilson, Ph.D. Center for Pharmacoeconomic.

Clinical errors - their causes and frequency in hospitals Prof Johanna Westbrook Prof Enrico Coiera Funded by: HCF Health & Medical Research Foundation.

The financial costs and benefits of alcohol The financial costs and benefits of alcohol Christine Godfrey Department of Health Sciences & Centre for Health.

Funding: Health Foundation, ESVS The GALA Trial General versus Local Anaesthesia for Carotid Endarterectomy Michael J Gough on behalf of the GALA Trial.

Sustaining Quality. “Expectations will always exceed capacity. The service must always be changing, growing and improving…”. Aneurin Bevan, 1948.

The Value of Reference Case Methods for Resource Allocation Decision Making Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics.

© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:

LifeCIT Development and pilot evaluation of a web-supported programme of Constraint Induced Therapy following stroke (LifeCIT) Meagher C 1, Conlon A 2,

Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.

Understanding Health Economics Nicola Cooper, PhD Professor of Healthcare Evaluation Research Department of Health Sciences University of Leicester

Benjamin Kearns, The University of Sheffield

How to Perform a Cost-Effectiveness Analysis

Rita Faria Research fellow at the Centre for Health Economics

Larissa Registry on CAS and CEA:

Alcohol, Other Drugs, and Health: Current Evidence

Markov model structure

David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research

Pooled Analysis of VA, ACAS, ACST-1 & GALA Trials

Cost Effective Studies

Mechanical thrombectomy

Economics of Public Health Nursing

Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.

Health care decision making

Preliminary analysis of a new measure of quality of patient decision making about research participation Peter Knapp, Jonathan Graffy, Peter Bower, Jo.

Dynamic treatment selection and medication for personalised blood pressure therapy using a Markov decision process model: a cost- effectiveness analysis.

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Payment and Funding Mechanisms

Introduction to Health Economics (1)

Presentation transcript:

Funding: Health Foundation, ESVS Economic evaluation alongside clinical trials: The GALA trial Manuel Gomes, Marta Soares, Jo Dumville, David Torgerson Dep. of Health Sciences - University of York

Funding: Health Foundation, ESVS Why is economic evaluation important? The objective of the budget holder is to maximise health gains from a fixed budget There is an opportunity cost associated with each choice Economic evaluation aims to inform decisions about resource allocation - value for money

Funding: Health Foundation, ESVS What is economic evaluation? Comparative analysis of competing interventions with respect to: costs health benefits Characterisation of uncertainty surrounding the decision Identify and make explicit the set of criteria used for decision making

Funding: Health Foundation, ESVS Main methods for economic evaluation Cost-effectiveness analysis Health benefits measured in natural units: event-free days Cost-utility analysis Health benefits expressed as a single measure combining quality gains (morbidity) and quantity gains (longevity) Quality Adjusted Life Years (QALYs)

Funding: Health Foundation, ESVS Economic evaluation potential results Differences in cost Differences in effectiveness New intervention is - more costly - less beneficial New intervention is - less costly - more beneficial New intervention is - less costly - less beneficial New intervention is - more costly - more beneficial NE quadrant NW quadrant SE quadrant SW quadrant + 0

Funding: Health Foundation, ESVS The GALA Trial Preliminary Economic Analysis Cost effectiveness analysis RCT based Perspective – health care provider Time horizon – 1 year Health outcome Event free survival (MI, stroke, death) Relevant resources

Funding: Health Foundation, ESVS The GALA Trial Unit Costs ResourceUnitUnit cost (£)Source WardDay170CIPFA Hospital ‘hotel’ costs Intensive therapy Unithour1328/24Dept Health High dependency Unithour584/24Dept Health Traineeminute0.7PSSRU Consultantminute4.5PSSRU Theatre & recovery room Nurse Sisterminute.68PSSRU Theatre Nurseminute.88PSSRU Overheadsminute2.39Sculpher et al. LA anaestheticsSurgery6.5BNF Consumables & drugs GA anaestheticsSurgery22.5BNF ShuntsUnit65Manufacturer PatchesUnit40Manufacturer Complications costs StrokeHRG1637Dep Health MIHRG1024Dep health

Funding: Health Foundation, ESVS The GALA Trial Resource Use Resource GA Endarterectomy (n=1753) LA Endarterectomy (n=1773) Hospital stay (days) (n=1737) (n=1756) Mean (SD)6 (7)6.2 (14) Time of surgery (minutes)(n=1711)(n=1717) Mean (SD)93 (33.5)93.2 (36) Post-surgery stay n (missing)1572 (165)1567 (189) Recovery room (hours)(n=1096)(n=1081) Mean (SD)6.4 (17.6) 5.5 (12.1) ITU (hours)(n=377)(n=340) Mean (SD)27.8 (71.4)23.9 (20.9) HDU (hours)(n=529)(n=542) Mean (SD)24.9 (19.6)23.7 (15.4) Surgery related resource use Trainee surgeon n (%)(242) 14(210) 12 Trainee anaesthetist n (%)(246) 16(213) 14 Shunts n (%)(738) 43(248) 14 Patches n (%)(861) 50(728) 42 Post-surgery adverse events Post-surgery stroke n (%)(68) 3.9(63) 3.6 Post-surgery MI n (%)(4) 0.2(9) 0.5

Funding: Health Foundation, ESVS The GALA Trial Preliminary Cost Estimation GA Endarterectomy (n=1753) LA Endarterectomy (n=1773) Mean (SD)Median (IQR)Mean (SD)Median (IQR) Theatre costs (465)1229 ( ) (499)1229 ( ) Acute care costs568.1 (2085)73 ( )482.8 (819)53 ( ) Hospital ‘hotel’ costs896.9 (1201)652 ( )956.6 (2531)627 ( ) Consumables & drugs82.1 (74)64 (0-179)43.8 (55)0 (0-64) Costs of adverse events65.3 (311)0 (0-0)66.9 (310)0 (0-0) Total costs2878 (2685)2470 ( )2821 (2810)2319 ( ) Differential mean cost* (95% CI) ϯ - 59 (-180 to 93) Differential mean event free survival (95% CI) 2.29 (-9.7 to 11.2) * LA minus GA Ϯ Standard t-tests

Funding: Health Foundation, ESVS The GALA Trial Ellipse Curves